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artin Briand, MS,* Isabelle Lemieux, PHD,* Jean G. Dumesnil, MD, FACC,* Patrick Mathieu, MD,*
mélie Cartier, MS,* Jean-Pierre Després, PHD, FAHA,*† Marie Arsenault, MD,* Jacques Couet, PHD,*
hilippe Pibarot, DVM, PHD, FACC*
uébec, Canada
OBJECTIVES This study sought to examine the association between the metabolic syndrome (MS) and the
progression of aortic stenosis (AS).
BACKGROUND It has been suggested that aortic valve sclerosis and its progression to AS are caused by an
atherosclerotic process. Metabolic syndrome is associated with a higher risk of vascular
atherosclerosis. Thus, we hypothesized that the atherogenic features of MS could negatively
influence disease progression and prognosis in patients with AS.
METHODS We retrospectively analyzed the data of 105 consecutive patients (age 69  12 years, 64 men)
with at least moderate AS. Of these patients, 40 (38%) had MS identified according to the
modified clinical criteria proposed by the National Cholesterol Education Program-Adult
Treatment Panel III. The hemodynamic progression of AS was assessed by the measurement
of the annualized decrease in valve area during the follow-up period of the study, which
averaged 28  13 months. Event-free survival was defined as the absence of death or aortic
valve replacement during follow-up.
RESULTS The hemodynamic progression of the stenosis was twice as fast (0.14  0.13 cm2/year vs.
0.08 0.08 cm2/year, p 0.008) and the three-year event-free survival was markedly lower
(44  8% vs. 69  6%, p  0.002) among patients with MS. In multivariate analysis, MS
was found to be a strong independent predictor of both stenosis progression (p  0.006) and
event-free survival (odds ratio 3.85, 95% CI 1.96 to 7.58, p  0.001).
CONCLUSIONS The present study is the first to report that MS is associated with a faster disease progression
and worse outcome in patients with AS. Such findings open new avenues of research and
provide a strong impetus for the elaboration of additional prospective studies focusing on this
association. (J Am Coll Cardiol 2006;47:2229–36) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.12.073Cardiology Foundation
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aalcific aortic valve stenosis (AS) has become the most
ommon cardiovascular disease in developed countries
fter coronary artery disease and hypertension (1). His-
orically, calcific AS has been considered degenerative be-
ause it was thought to be the result from aging and wear
nd tear of the aortic valve. However, this perception has
hanged over the years with the publication of several studies
howing that the calcific AS lesions shares many histologic
imilarities with atherosclerosis (1–5). Furthermore, the devel-
pment and progression of AS are linked to various traditional
isk factors for coronary artery disease (6–15). Hence these
ndings suggest that calcific AS is not a degenerative disease
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005, accepted December 30, 2005.esulting from decades of repetitive mechanical stress, but
ather an active disease related to atherosclerosis.
Previous studies evaluating the rate of hemodynamic
rogression in patients with AS have shown that the average
ate of decrease in aortic valve effective orifice area (AVA) is
pproximately 0.1 cm2/year (5,16,17). However, the rate of
tenosis progression may vary extensively from one patient
o another. It is thus crucial to identify the independent
linical and metabolic factors that determine the progression
f AS because this information would eventually contribute
o developing new therapeutic approaches to delay or stop
tenosis progression, thus avoiding the need for aortic valve
eplacement (AVR).
The metabolic syndrome (MS) is a cluster of metabolic
erturbations largely resulting from an excess accumulation
f abdominal fat. Metabolic syndrome components include
roatherogenic dyslipidemia as well as proinflammatory and
rothrombotic abnormalities linked to in vivo insulin resis-
ance, such as fasting hyperinsulinemia, hypertriglyceride-
ia, low high-density lipoprotein (HDL) cholesterol, ele-
ated apolipoprotein B, small low-density lipoprotein
LDL) particles, endothelial dysfunction, elevated cytokines
nd C-reactive protein (CRP) levels, and reduced adiponec-
in concentrations (18,19). The prevalence of MS is esti-
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Metabolic Syndrome and Aortic Stenosis June 6, 2006:2229–36ated to be approximately 25% in the Western world
opulation (19,20). Previous studies have shown that the
resence of features of MS is predictive of an increased risk
f coronary artery disease, independent of traditional risk
actors (21). We hypothesized that the proatherogenic and
roinflammatory features of MS could accelerate the pro-
ression of AS and thus precipitate the occurrence of
dverse outcomes. The objective of this retrospective study
as thus to determine the impact of MS on hemodynamic
rogression and clinical outcomes of AS.
ETHODS
atient population. All patients examined in our echocar-
iography laboratory between August 1999 and July 2004
ho were found to have at least moderate AS defined by an
VA 1.5 cm2 and who had a minimum of two echocar-
iograms separated by at least six months were eligible for
his study. Exclusion criteria were as follows: 1) presence of
ymptoms; 2) left ventricular ejection fraction 50%, 3)
resence of congenital heart disease (other than bicuspid
ortic valve); 4) at least mild aortic or mitral regurgitation;
) subaortic obstruction precluding measurement of AVA;
) history and echocardiographic features of rheumatic heart
isease; and 7) previous aortic valve surgery. The occurrence
f cardiac events during follow-up was recorded and docu-
ented. For the assessment of outcome, end points were
efined as death or AVR (16,17).
oppler echocardiography. All patients underwent a
omprehensive Doppler echocardiographic examination
ith commercially available ultrasound systems. Doppler
chocardiographic measurements included the left ventric-
lar stroke volume, the peak and mean transvalvular gradi-
nts using the modified Bernoulli equation, and the AVA
sing the standard continuity equation. Particular care was
aken to record the maximum aortic jet velocity. For
ssessment of hemodynamic progression, echocardiographic
tudies separated by at least six months were used. When
atients had two or more serial echocardiograms, hemody-
amic progression between the first and last studies was
alculated. Annualized changes in peak and mean gradients
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
AS  aortic stenosis
AVA  aortic valve area
AVR  aortic valve replacement
CRP  C-reactive protein
HDL  high-density lipoprotein
LDL  low-density lipoprotein
MS  metabolic syndrome
NCEP-ATPIII  National Cholesterol Education
Program-Adult Treatment Panel IIImm Hg/year) and AVA (cm2/year) were calculated by sividing the difference between the first and last measure-
ents by the time between examinations. The degree of
alcification of the aortic valve was scored according to the
riteria proposed by Rosenhek et al. (17): 1) no calcification;
) mildly calcified (isolated, small spots); 3) moderately
alcified (multiple larger spots); and 4) heavily calcified
extensive thickening/calcification of all cusps).
linical and laboratory data. Clinical data included age,
ender, etiology of valvular stenosis, history of smoking, and
ocumented diagnoses of hypertension (patients receiving
ntihypertensive medications or having known but untreated,
ypertension [blood pressure 140/90 mm Hg]), hypercho-
esterolemia (patients receiving cholesterol-lowering medica-
ion or, in the absence of such medication, having a total
lasma cholesterol level 240 mg/dl), diabetes (fasting glu-
ose 7 mmol/l), obesity (body mass index 30 kg/m2),
nd coronary heart disease (history of myocardial infarction
r coronary artery stenosis on coronary angiography). Fur-
hermore, a fasting plasma lipid profile (including total
holesterol, LDL cholesterol, HDL cholesterol, and triglyc-
ride levels) and blood pressure were assessed in the resting
tate in all patients. Information on statin and angiotensin-
onverting enzyme (ACE) inhibitor treatment was also
ecorded. Among the 105 patients included in this study, 45
nderwent an AVR during follow-up. In 20 of these 45
atients, plasma was collected at the time of operation and
tored at 80°C. In these samples, insulin, apolipoprotein
, the size of LDL particles, CRP, and adiponectin were
etrospectively measured using methods used on a routine
asis in our laboratory (22,23).
dentification of patients with MS. The clinical identifi-
ation of patients with the features of MS was based on the
odified criteria proposed by the National Cholesterol Edu-
ation Program-Adult Treatment Panel III (NCEP-ATPIII)
24). Because waist circumference was not measured in this
ample, body mass index was substituted for waist circum-
erence as an index of obesity (25). Patients were considered
o have MS when three of the five following criteria were
resent: 1) body mass index 30 kg/m2; 2) fasting glycemia
110 mg/dl; 3) triglycerides 150 mg/dl; 4) HDL choles-
erol 40 mg/dl in men and 50 mg/dl in women; and 5)
ystolic/diastolic blood pressures 130/85 mm Hg.
tatistical analysis. Continuous data were expressed as
ean  standard deviation and compared using the un-
aired Student t test. Categorical data were expressed as a
ercentage and compared with the chi-square test. A
ogarithmic transformation was used when variables did not
ollow a normal distribution. A forward multiple linear
egression analysis was used to identify the independent
redictors of the hemodynamic progression of AS. Proba-
ilities of event-free survival were obtained by Kaplan-
eier estimates for the levels of various risk factors. The
ffect of these factors on survival was assessed by means of
imple and multiple Cox proportional hazards models.
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atient characteristics. Of the 105 subjects, 40 (38%) met
he clinical criteria of MS. The baseline characteristics and
he hemodynamic progression of AS in the different groups
re shown in Table 1. The patients with MS had a higher
revalence of hypertension, diabetes, obesity, smoking, his-
ory of hypercholesterolemia, and therapy with statins or
CE inhibitors compared with patients without MS. Also,
atients with MS tended to have a higher prevalence of
oncomitant coronary artery disease (70% vs. 51%, p 
.08) compared with patients without MS. Moreover, as
xpected, patients with MS had significantly higher plasma
evels of glucose and triglycerides and lower levels of HDL
holesterol. However, they had significantly lower total and
DL cholesterol. The more frequent use of statins in MS
atients likely explains the lower plasma levels of LDL
holesterol in these patients. Despite the higher number of
raditional cardiovascular risk factors such as age 70 years,
ale gender, hypertension, diabetes, hypercholesterolemia,
moking, and obesity in the MS group, the global Framing-
able 1. Patient Characteristics
Variables All Patients (n 
ge, yrs 69  12
ale (%) 65 (62%)
ody mass index 27  4
ody surface area (m2) 1.83  0.2
icuspid valve 17 (16%)
isk factors
Hypertension (%) 85 (81%)
Diabetes (%) 33 (31%)
Obesity (%) 31 (30%)
History of hypercholesterolemia (%) 67 (64%)
History of smoking (%) 53 (50%)
Number of risk factors 4.0  1.7
Framingham score 8.1  3.7
Degree of aortic valve calcification 3.3  0.6
edication
Treatment with statins (%) 60 (57%)
Treatment with ACE inhibitors (%) 49 (47%)
aboratory values
Fasting glycemia (mg/dl) 115  35
Total cholesterol (mg/dl) 175  35
Triglycerides (mg/dl) 119  48
HDL cholesterol (mg/dl) 52  13
LDL cholesterol (mg/dl) 99  30
Total cholesterol/HDL cholesterol 3.5  0.9
ortic valve hemodynamics
Baseline peak aortic velocity (ms1) 3.2  0.6
Baseline peak gradient (mm Hg) 43  17
Baseline mean gradient (mm Hg) 25  11
Baseline AVA (cm2) 1.08  0.2
Baseline stroke volume (ml) 79  19
Progression rate of peak velocity (ms1/yr) 0.19  0.2
Progression rate of peak gradient (mm Hg/yr) 5.5  8.6
Progression rate of mean gradient (mm Hg/yr) 3.5  5.7
Progression rate of AVA (cm2/yr) 0.10  0.1
Progression rate of stroke volume (ml/yr) 3  9
ata are mean  SD or number of patients (%).
ACE  angiotensin-converting enzyme; AVA  aortic valve area; HDL  higham risk score was slightly lower in this group, a result ahich was essentially related to the lower LDL levels in MS
roup compared with patients without MS.
redictors of AS progression. The mean baseline AVA
as 1.08  0.24 cm2, and 40% of the patients had severe AS
valve AVA 1.0 cm2) at baseline. The mean time interval
etween the first and last echocardiographic examination was
8 13 months. The rate of progression of peak transvalvular
elocity, peak gradient, mean gradient, and AVAwas0.19
.27 ms1/year,6 9 mm Hg/year,4 6 mm Hg/year,
nd 0.10  0.11 cm2/year, respectively. In univariate analy-
is, only baseline severity of AS, male gender, and MS were
ignificantly associated with hemodynamic progression of AS
Fig. 1). Patients with moderate AS at baseline had faster
rogression of AVA (0.12  0.11 cm2/year vs. 0.07 
.10 cm2/year, p  0.02), but this difference was no longer
ignificant when examining relative changes (10  8%
s.8 11%, pNS).Male patients had a significantly (p
.02) higher rate of progression of AVA. However, AVA was
lso higher at baseline (1.15  0.23 cm2) in men than in
omen (0.96  0.21 cm2, p  0.001). No significant
) MS (n  40, 38%) No MS (n  65, 62%) p Value
69  10 69  13 NS
28 (70%) 37 (57%) NS
30  5 26  3 0.001
1.94  0.23 1.77  0.17 0.001
5 (13%) 12 (18%) NS
37 (93%) 48 (74%) 0.002
23 (58%) 10 (15%) 0.001
23 (58%) 8 (12%) 0.001
35 (88%) 32 (49%) 0.001
26 (65%) 27 (42%) 0.03
4.8  1.1 3.0  1.4 0.001
7.0  3.9 8.8  3.4 0.015
3.3  0.6 3.3  0.6 NS
31 (78%) 29 (45%) 0.002
26 (65%) 23 (35%) 0.006
131  43 103  22 0.001
159  31 185  33 0.001
136  55 107  39 0.007
45  9 56  13 0.001
88  24 107  32 0.004
3.6  0.7 3.4  1.0 NS
3.2  0.5 3.2  0.7 NS
43  13 42  20 NS
25  8 25  12 NS
1.09  0.25 1.07  0.23 NS
81  20 78  18 NS
0.28  0.30 0.13  0.24 0.006
8.4  10.5 3.7  6.7 0.006
5.0  6.3 2.6  5.1 0.03
0.14  0.13 0.08  0.08 0.008
5  11 3  8 NS
ity lipoprotein; LDL  low-density lipoprotein; MS  metabolic syndrome.105
1
4
7
1ssociation was found between the hemodynamic progres-
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Metabolic Syndrome and Aortic Stenosis June 6, 2006:2229–36ion of AS and age, hypertension, obesity, history of
moking, Framingham risk score, number of traditional
ardiovascular risk factors, coronary artery disease, degree of
ortic valve calcification, statin therapy, or ACE inhibitor
herapy. There was a trend for more rapid progression of
radient in patients with a history of hypercholesterolemia
6.5  9.5 mm Hg/year vs. 3.6  6.5 mm Hg/year,
 0.09) as well as in patients with diabetes (7.0 9.5 mm
g/year vs. 4.2  6.5 mm Hg/year, p  0.09); this trend
as not observed for progression of AVA. The rate of
tenosis progression was twice as high among patients with
S compared with those without MS (peak gradient
rogression 8.4  10.5 mm Hg/year vs. 3.7  6.7 mm
g/year, p  0.006; AVA progression 0.14  0.13
m2/year vs.0.08 0.08 cm2/year, p 0.008). There was
weak correlation between the number of NCEP-ATPIII
able 2. Metabolic Markers in the Subset of 20 Patients With
vailable Fasting Plasma
Variables
MS
(n  11, 55%)
No MS
(n  9, 45%)
p
Value
asting glycemia (mg/dl) 140  54 97  22 0.045
otal cholesterol (mg/dl) 147  39 197  23 0.004
riglycerides (mg/dl) 115  44 89  44 NS
DL cholesterol (mg/dl) 42  8 62  19 0.005
DL cholesterol (mg/dl) 85  27 124  39 0.013
otal cholesterol/HDL
cholesterol
3.6  0.6 3.1  0.6 0.07
OG fasting insulin 0.19  0.30 0.06  0.11 0.044
polipoprotein B (g/l) 0.74  0.30 0.78  0.09 NS
DL peak particle size (Å) 260.0  3.3 263.7  2.7 0.015
ercent large LDL particles 34  23 67  13 0.001
ercent medium LDL particles 34  10 22  7 0.007
ercent small LDL particles 32  19 11  9 0.006
-reactive protein (mg/l) 5.84  4.41 2.45  2.82 0.06
OG adiponectin 0.62  0.36 0.89  0.16 0.048
igure 1. Rate of progression of aortic valve area (AVA) with presence
orange bars) or absence (blue bars) of age 70 years, male gender,
ypertension (HPT), obesity, history of hypercholesterolemia (Hyperchol),
istory of smoking, diabetes, and metabolic syndrome (MS).s
ata are mean  SD.
LOG  logarithmic value; other abbreviations as in Table 1.omponents of MS and progression rate of AVA (r  0.24,
 0.02).
In the whole group (105 patients), there was a significant
orrelation between the annualized decrease in AVA and
asting glycemia (r  0.32, p  0.003). On the other
and, no significant correlation was found between rate of
rogression of AVA or gradients and total cholesterol,
DL cholesterol, LDL cholesterol, triglyceride concentra-
ions, and the total/HDL cholesterol ratio.
In the subgroup of 20 patients for whom plasma was
vailable for measurement of additional markers of MS,
atients with MS (11 of 20, 55%) had significantly smaller
DL particle size, higher fasting insulin, lower adiponectin,
nd higher CRP, although this difference did not reach
tatistical significance (Table 2). There were trends for the
ate of progression of AVA to be associated with LDL
article size (r 0.38, p 0.11) and with insulin levels (r 
0.40, p  0.09).
In multivariate analysis, MS (p 0.006) and baseline AS
everity (i.e., baseline AVA (p  0.002) or peak gradient
p  0.05) were the only independent predictors of the
rogression of AS (Table 3). The MS remained a strong
ndependent predictor (standardized coefficient: 0.25 and
 0.009 in the model predicting AVA progression rate;
tandardized coefficient: 0.33, p  0.001 in the model
redicting peak gradient progression rate) after adjusting for
ge, baseline AS severity, history of hypercholesterolemia,
iabetes, and Framingham score. Nonetheless, the impact
f MS on stenosis progression seemed to be more important
mong patients with a Framingham score 8 than in those
ith a lower score (Fig. 2).
Insulin resistance is an important feature of MS. How-
ver, among patients with diabetes, the patients with MS
ad a much faster progression of gradient compared with
hose with no MS (11 13 mm Hg vs. 3 7 mm Hg, p 
.003). In addition, among the patients without MS, there
as no significant difference between patients with diabetes
3  7 mm Hg) versus those without diabetes (4  7 mm
g). Moreover, MS remained a strong independent predic-
or of stenosis progression after adjusting for diabetes.
hese findings support the notion that the effect of MS on
able 3. Independent Determinants of the Hemodynamic
rogression of Aortic Stenosis
Rate of Progression
AVA Peak Gradient
Variables
STD
Coefficient
p
Value
STD
Coefficient
p
Value
aseline AVA 0.29 0.002 — —
aseline peak gradient — — — 0.05
etabolic syndrome 0.26 0.006 0.27 0.006
he variables tested in the multivariate analysis were age, gender, baseline severity of
he stenosis (AVA or peak gradient), degree of aortic valve calcification, hypertension,
iabetes, hypercholesterolemia, obesity, smoking, Framingham score, number of risk
actors, metabolic syndrome, coronary artery disease, and treatment with statins or
ngiotensin-converting enzyme inhibitors. Only the variables that reached statistical
ignificance in multivariate analysis are shown in this table.
AVA  aortic valve area; STD coeff.  standardized coefficient.tenosis progression is in large part independent of that of
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June 6, 2006:2229–36 Metabolic Syndrome and Aortic Stenosisiabetes. Finally, statin therapy had no significant effect on the
rogression of the disease both in patients with MS and in
hose without MS (Fig. 3).
redictors of clinical outcomes. During follow-up, 53 end
oints were observed, including 45 AVRs and 8 deaths: 5
ardiac and 3 noncardiac. Of the five cardiac deaths, there
as one sudden death and four deaths related to acute
yocardial infarction. The event-free survival in this series
as 59  5% at three years and 33  9% at five years. The
S was the most powerful predictor of outcome (Fig. 4 and
able 4). Three-year event-free survival was 44  8% in
atients with MS versus 69  6% in those without MS
p  0.002) (Fig. 4). The other predictors of outcome were
ale gender (p  0.005), a peak gradient 65 mm Hg
peak velocity4 m/s) at baseline (p 0.004), and diabetes
p 0.05). There was also a trend for a lower event-free rate
n patients with an aortic valve calcification score 3 (p 
.065) as well as in patients with a history of smoking (p 
.06). In multivariate analysis, male gender (p  0.03), a
igure 2. Rate of progression of aortic valve area (AVA) among the two
roups separated according to the median value of the Framingham score
n patients with metabolic syndrome (MS) (orange bars) and those without
S (blue bars). †Significant difference versus group 2 (p  0.05).
igure 3. Rate of progression of aortic valve area (AVA) among the two
roups separated according to the presence or absence of statin therapy in
atients with metabolic syndrome (MS) (orange bars) and those withouth
S (blue bars). *Significant difference versus group 1 (p  0.05);
significant difference versus group 2 (p  0.05).aseline peak gradient 65 mm Hg (p  0.001), and MS
p  0.001) were the only independent predictors of
utcome (Table 4). The risk of outcome was increased
.85-fold (95% confidence interval 1.96 to 7.58) in patients
ith MS compared with patients without MS.
ISCUSSION
he contribution of the present study is to provide, for the
rst time, evidence that MS is a strong independent
redictor of stenosis progression and clinical outcome in
atients with AS. These findings are clinically relevant given
hat MS is a frequent and modifiable condition largely
esulting from overweight/obesity and a sedentary lifestyle.
revious studies have reported that the prevalence of MS
as estimated to reach about 25% in the Western world
opulation (19,20). In our sample of elderly patients with
S, the prevalence of MS was up to 38%.
omparison with previous studies of AS progression. Pre-
ious studies have identified several factors predictive of
aster progression of AS, including the stenosis severity and
he degree of aortic valve calcification at baseline, advanced
ge, smoking, obesity, hypercholesterolemia, high total/
DL cholesterol ratio, diabetes, coronary artery disease,
nd absence of statin treatment (5,8,12–17,26–34). In the
resent study, the baseline severity of AS was also found to
e an independent risk factor for stenosis progression. Other
actors also previously reported to be independent predictors
f progression were not found to be as such in the present
tudy. However, it should be pointed out that factors such as
alve calcification and coronary artery disease are more likely
urrogate markers rather than metabolic determinants of the
isease. Moreover, the influence of MS was not taken into
ccount in these previous studies.
The association between hypercholesterolemia and AS
igure 4. Kaplan-Meier analysis of event-free survival in 40 patients with
etabolic syndrome (MS) compared with 65 patients without MS.emodynamic progression remains unclear. One study re-
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Metabolic Syndrome and Aortic Stenosis June 6, 2006:2229–36orted a modest correlation between the change in AVA
nd the change in plasma LDL cholesterol level during
ollow-up (30), whereas other studies reported no correla-
ion between LDL cholesterol levels and stenosis progres-
ion (31,34). Accordingly, in the present study, there was no
ignificant correlation between history of hypercholesterol-
mia or plasma LDL cholesterol level at baseline and
tenosis progression.
Patients with MS are at higher global risk of cardiovas-
ular diseases and thus require more aggressive therapy.
ccordingly, in the present study the proportion of patients
reated with statins and/or ACE inhibitors was markedly
igher in the MS group. Nevertheless, this aggressive
reatment was not able to slow the stenosis progression of
atients with MS (Fig. 3). Indeed, although lipid-lowering
herapy was successful in achieving the recommended
oal of the NCEP-ATPIII, i.e., an LDL cholesterol level
f 100 mg/dl, in all patients with MS, the average rate
f progression of their stenosis was nonetheless twice as
ast compared with patients without MS.
Another major finding of this study is that MS is
ndependently associated with a worse outcome in patients
ith AS. This result is consistent with the much faster
emodynamic progression measured by Doppler echocardi-
graphy in the MS group. The strong agreement between
he results of hemodynamic progression and those of clinical
utcome gives further robustness to the conclusion that MS
s a powerful independent predictor of the progression of
alcific AS. The other factors previously reported as inde-
endent predictors of clinical outcome in AS were patient’s
ge and functional status, baseline severity of AS, and
egree of aortic valve calcification (16,17,33,35). However,
s mentioned above, most of these factors can be viewed as
arkers rather than determinants of the disease. Hence,
lthough these factors may be particularly useful for risk
tratification of AS patients (16,17,33), they cannot be used
o identify new therapeutic targets for this disease.
otential mechanisms responsible for the association
etween MS and AS progression. The NCEP-ATPIII
as recognized that MS represents a cluster of atherogenic,
therothrombotic, and inflammatory abnormalities (24).
ndeed, there are several features of MS that could be
nvolved in the progression of aortic valve disease, including
able 4. Predictors of Outcome in Univariate and Multivariate A
Variable
Number of Patients
With Variable (%) p
ale 65 (62)
egree of aortic valve calcification 3 42 (40)
eak gradient 65 mm Hg 14 (13)
iabetes 33 (31)
istory of smoking 53 (50)
etabolic syndrome 40 (38)
utcome was defined as the combined end point of aortic valve replacement or deat
n the footnote of Table 3. Only the variables that had a p value 0.1 in univariate
CI  confidence interval.he following:. The presence of small, dense LDL particles may en-
hance the infiltration of LDL into the aortic valve
leaflets. Moreover, these small, dense particles have an
increased susceptibility to oxidation. Small LDL parti-
cles may also carry other proatherogenic factors, such as
ACE and CRP, into the aortic valve lesions (36,37).
The proinflammatory and proatherogenic effects of
angiotensin II, the enzymatic product of ACE, are well
established and recent reports suggest that CRP is not
only a marker of inflammation but that it may also
participate in the disease process (38,39).
. It is well known that HDL cholesterol has antioxidant
and antithrombogenic effects (40). Hence, the reduction
of HDL cholesterol as well as the presence of small,
dense LDL particles associated with MS could predis-
pose to the production of oxidized LDL and thus
promote inflammation and calcification within aortic
valve leaflets (3,41–43).
. It is now well accepted that atherosclerosis has an inflam-
matory component and that its related markers predict
acute coronary events. Several studies also showed that
inflammation is involved in the pathogenesis of nonrheu-
matic AS (37,43–45). The expanded abdominal adipose
depot in patients with MS could represent an important
source of cytokine (e.g., interleukin-6, tumor necrosis
factor-alpha) production (46–49). Interleukin-6 has a
proinflammatory and proatherogenic effects, and it stim-
ulates hepatic production of CRP (38,46,47). Hence,
the presence of abdominal obesity in patients with MS
could exacerbate the inflammatory response to various
environmental stimuli.
. Adiponectin is an adipocyte-specific protein with an
insulin-enhancing activity as well as antiinflammatory
and antiatherogenic properties, which has been shown
to have a protective effect on the initiation and progres-
sion of atherosclerosis (50). It is well known that plasma
adiponectin levels are reduced in the presence of obesity
and/or MS (22). Hence, it is possible that hypoadi-
ponectinemia associated with MS would play a role in
the progression of calcific AS. Additional studies will
now be needed to identify which feature(s) of MS are
responsible for the faster progression of AS. This
knowledge could lead to the development of new
is
Univariate Analysis Multivariate Analysis
e Risk Ratio (95% CI) p Value Risk Ratio (95% CI)
2.58 (1.33–5.01) 0.03 2.09 (1.06–4.10)
1.74 (0.97–3.13) — —
2.60 (1.36–5.00) 0.001 3.13 (1.56–6.30)
1.70 (0.99–2.93) — —
1.74 (0.98–3.06) — —
2.46 (1.40–4.32) 0.001 3.85 (1.96–7.58)
e variables tested in univariate and multivariate analysis are the same as those listed
is are shown in this table.nalys
Valu
0.005
0.065
0.004
0.05
0.06
0.002
h. Thpotentially important therapeutic targets.
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June 6, 2006:2229–36 Metabolic Syndrome and Aortic Stenosislinical implications. The results of this study have im-
ortant clinical implications. Indeed, MS is a potentially
reventable and modifiable condition that often goes undi-
gnosed and untreated. Hence, in light of our results,
atients diagnosed with AS should be systematically
creened for the presence of MS, and if found, patients
hould probably be followed up more closely with regard to
he evolution of their disease and the appearance of symp-
oms. Moreover, many of the features of MS are not
eversed by the pharmacologic treatment of traditional risk
actors. To this effect, it should be pointed out that the two
harmacological agents (i.e., statins and ACE inhibitors)
hat are currently under the most scrutiny for potentially
elaying AS progression (1,30,31,34,51–53) have no or
ittle effect on the metabolic perturbations associated with
S (54,55). The treatment of the features of MS requires
ggressive changes in lifestyle habits, such as increasing
hysical activity and implementing dietary changes leading
o weight reduction. The main challenge with regard to the
atter is patient compliance, and the findings of the present
tudy should provide added motivation for patients with the
ombination of AS and MS to undergo such changes.
ewer pharmacologic approaches that specifically target some
f the key causal mechanisms of MS might also be considered
s becoming part of the treatment of these patients (19,56).
dditional prospective studies will, of course, be necessary to
etermine whether the evolution of AS can actually be slowed
y a more aggressive treatment of MS.
tudy limitations. The study was retrospective in nature.
atients with MS might therefore be more likely to have
epeated echocardiographic studies, thus biasing the results
o show more rapid progression in that group. This study
lso included a relatively small number of patients. Hence,
he apparent lack of significant association between stenosis
rogression and some clinical factors, including history of
ypercholesterolemia, diabetes, and statin therapy, may be a
ype II error because of the small sample size. Nonetheless,
his limitation does not affect the validity of the main result
f this study, which is the demonstration of a strong
ssociation between MS and AS progression.
Plasma was not available in the vast majority of the
atients. It was thus not possible to investigate the potential
echanisms responsible for the more rapid progression of
he aortic valve lesions in the presence of MS.
The waist circumference was not measured in this study.
lternatively, to identify patients likely to have MS, we used
body mass index 30 kg/m2, which has been shown to
orrespond to the NCEP-ATPIII cutoff values of 102 cm in
en and 88 cm in women for waist circumference (57).
ody mass index alone is not necessarily a good marker of
bdominal obesity and of MS. Nonetheless, when combined
ith the other metabolic criteria of the NCEP-ATPIII
uidelines, it is useful for identifying individuals with MS
18,19,39). In fact, its use in this circumstance seems to be
ighly specific, but its sensitivity is probably lower than
aist circumference (58). Hence, the prevalence of MS inhis study might actually have been higher had waist
ircumference been used as a criteria for its detection,
hereas the likelihood of false positives is probably very low.
In conclusion, this is the first study to report that MS is
ighly prevalent in patients with AS and that it is a strong
nd independent predictor of disease progression and oc-
urrence of adverse outcomes. Such findings open new
venues of research and provide a strong impetus for the
laboration of prospective studies focusing on the aggressive
reatment of the features of MS in patients with AS.
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